Our key product is Enteral Ventilation (EVA) technology, that supplies liquid oxygen to premature babies with serious respiratory problems through Gut-Mediated Oxygen Delivery. The program is at the clinical trial stage.
As a drug discovery venture originating from Kyoto University, we are developing RN-501, a novel boron-containing drug for boron-neutron capture therapy (BNCT), a next-generation cancer radiation therapy targeting intractable cancers. Through proprietary boron carbide nanoparticle technology and polyglycerol modification, RN-501 achieves high tumor selectivity and accumulation, along with potent cancer-killing and immune-activating effects with a single intravenous administration, overcoming the limitations of existing drugs. As Japan's first and the world's first nano-BNCT drug, we aim for early societal implementation.
B-Lab is a biotechnology venture originating from Konan University, engaged in the production and sales of β-1,3-1,6-glucan nanoparticles and betaine-derived aqueous solutions. Based on biomimetic chemistry, these products drive the development of next-generation, safe, and environmentally harmonized biomaterial technologies applicable to the food, cosmetic, pharmaceutical, agricultural, and chemical industries.
We sell ceramic filter columns for the purification and high-purity refinement of fine chemicals, including pharmaceuticals. Our columns are used from chemical and pharmaceutical research through to manufacturing, delivering approximately five times the separation performance of conventional products to improve target-compound purity. They are reusable, enabling significant cost reduction, and can be deployed immediately by simply replacing existing disposable cartridges on current equipment. From Kyoto, we provide high-performance, environmentally responsible, and cost-effective purification technology to customers worldwide.
A Kyoto-based startup has developed the world's first cell therapy enabling nerve regeneration using ES/iPS cell-derived Schwann cells. This breakthrough enables large-scale production of cells previously difficult to mass-produce, paving the way for clinical trials.
